A VERTICALLY INTEGRATED MULTI-STATE CANNABIS ROLL-UP INVESTMENT

MANAGEMENT PRESENTATION | OCTOBER 2017

THE MPX DIFFERENCE

Strong execution in an investment opportunity to build a dominant and highly profitable cannabis company

- Cannabis sector growing faster than any other sector of the U.S. economy
- Already one of the largest North American cannabis companies by revenue
- Building on a highly profitable platform for growth in Arizona
- Expanding into adult use markets (Nevada & Massachusetts)
- Attractively priced expansion opportunities
- Expanding in states with strong barriers to entry
- Strong and experienced management team

- Strong drivers of organic growth
  - Significant market growth
  - Capacity expansion
  - Innovation
  - Brand leverage
  - Skill and knowledge transfer to new operations, accelerating market capture and margin expansion
- Well-capitalized
  - US$38.2 million in equity raised since Jan 2017
  - US$25 million credit facility to fuel expansion
  - Cash flows from AZ operations more than cover operating costs

Capitalizing on the U.S. arbitrage cannabis opportunity

Leveraging balance sheet and access to capital to pursue aggressive roll-up strategy in large but fragmented market

Pursuing Canadian license

THE TIME IS NOW RIGHT

Bloomberg Markets

*"The legal cannabis industry in the U.S. may grow to **$50 billion** in the next decade, expanding to more than **eight times** its current size."*

FT FINANCIAL TIMES

*"Marijuana is the latest craze to sweep through the **tech world**, as entrepreneurs and investors look to **cannabis to be the next big thing**."*

Forbes

*"The U.S. economy doesn't **spawn an entirely new industry** very often, and legal pot may well be the **best ground-floor opportunity** we've seen **since the early days of the Internet!**"*

Forbes

*"Marijuana investors repeat the tale of **Joe Kennedy…**who **made a fortune** from the re-legalization of alcohol…. They are **positioning to have market share** and established market presence **when marijuana prohibition lifts.**"*

a

*"We are at an inflection point in this country. Not since the **end of alcohol prohibition has an opportunity existed like the cannabis industry**. With an estimated $50bn in annual black market sales, this is truly a **once in a lifetime moment**. Every facet of the industry offers **huge growth and profits.**"*

DANIEL KARTEN, THE ARTCAN GROUP

Marijuana Business Daily™

The most trusted cannabusiness news source since 2011

*"There is **no better place or time** right now for **bold moves and big bets**…in the cannabis industry…these businesses are quite literally making history."*

MARIJUANA BUSINESS DAILY

THE ARCVIEW GROUP

*"It wasn't until we got into the election of 2012 that we saw **a whole new wave of investors** and entrepreneurs entering the industry…That was really a signal for people that it was **a lot safer**…There is too much money and too few deals."*

STEVE DEANGELO, ARC VIEW GROUP

THE U.S. CANNABIS MARKET



>200 million
people in states with legalized medical cannabis

>2.3 million
registered card holders [1]

63 million
people in states with recreational use

- Cannabis remains a Schedule I controlled substance at U.S. Federal level
- Cannabis legislation implemented state-by-state
- Legalization momentum accelerating:
  - medically in 30 states
  - recreationally in 8 states



Source: executive summary: the state of legal marijuana markets, 4th edition (archives market research and new frontier), 2016

[1] Marijuana Business Daily; November 14, 2016

WHAT YOU NEED TO KNOW ABOUT MEDICAL CANNABIS

- Growing body of anecdotal and scientific evidence of cannabis benefits in symptom management
  - Neuropathic pain associated with HIV/AIDS and other conditions[1]
  - Nausea and vomiting associated with chemotherapy[2]
  - Inflammation
  - Chronic pain[3]
  - Epilepsy
  - Sleep disorders
  - Multiple sclerosis



Significant, underpenetrated market

Medical study showed a **64% reduction in opioid use** among patients with chronic pain who used cannabis

64% of Americans' support legalization of medical marijuana - a record high

1 Ellis RJ, et al 2009; Haney M, et al 2005.
2 Tramer MR et al 2001.
3 Ware MA, et al 182(14): E694-701; Lynch ME, et al 2003; Martin Sanchez E, et al 2009.

Source: Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education; 2016 Marijuana Business Daily.

Source: Boehnke et al J Pain. 2016 Mar 18. pii: S1526-5900(16)00567-8)

Source: Gallup survery October 2017

FRAGMENTED U.S. MARKET – IDEAL FOR ROLL-UP STRATEGY

Estimated Number of Cannabis Businesses in The U.S.: 2016[1]	
Medical Dispensaries / Recreational Stores	3,400 – 4,700
Infused Product Manufacturers	900 – 1,300
Wholesale Cultivators	2,500 – 4,500
Testing Labs	90 – 120
Ancillary Services, Technology & Products Companies	14,000 – 22,000

Large number of fast growing but undercapitalized operations with limited access to capital = ideal roll-up scenario

- Attractive valuations
- Drive synergies & improve margins
- Boost cultivation & production capacity
- Leverage existing brands across states

Major opportunity to drive rapid shareholder value creation

[1] Marijuana Business Daily; 2016

MPX OPERATIONS AND 2017/2018 TARGETS

2018 targets:
New Jersey, Ohio, Michigan



GreenMart of Nevada
Las Vegas, Nevada
(99% owned)

- Operational production, cultivation, and professional kitchen
- Facility located in Las Vegas with 42 million visitors per year

Health for Life
Mesa, Arizona (100% owned)

- Two operational dispensaries in Mesa, Arizona,
- Third dispensary under development
- Sizeable and growing cultivation and production capacity
- Best-in-class operational and commercial practices

Q4 Target #1
Arizona

- Vertically integrated production, cultivation and retail opportunity
- Has operational history

IMT, LLC
Boston, Massachusetts
(51% owned)

- Cultivation, production and retail dispensary licenses
- Assets under development
- Tightly regulated market, where IMT has first-mover advantage

Q4 2017 Targets #2 a, b & c
Maryland

- Three dispensary licenses opportunities
- One production license
- One supply contract (flower & trim)
- All located within Baltimore-Bethesda area

CANADIAN DEVELOPMENT PROGRESSING

The market opportunity:

- Canada to introduce legalized sales for adult use in July 2018
- Progressing through Health Canada application process to obtain Licensed Producer status
- Focus on launching MPX concentrates brand in Canada

$ 10+ billion

adult consumer market opportunity in Canada[1]

3.4 million Canadian marijuana users

Nationwide legalization

Potential for new product forms & devices

$ 2.1 billion

medical cannabis market opportunity in Canada[1]

MPX operations:

Option to expand to 475,000 sqft

Completed initial work to build out the Company's Owen Sound facility

Commencing full build-out for pre-licensing inspection

Anticipate completion by July 2018

>70,000 sqft ~8,000 kg cannabis per year

[1] VIII Capital, Cannabis Sector, July 2017

MPX's VERTICALLY INTEGRATED U.S. ASSETS

CULTIVATION & PRODUCTION

DISPENSARIES

BRANDS & PRODUCTS

SEED TO DISTRIBUTION RARE IN THE CANNABIS INDUSTRY

VERTICALLY INTEGRATED CANNABIS OPERATIONS IN THE U.S. ARE SCARCE

Cultivate & Grow

- Scalable facilities
- Low cost production
- Chemical free/organic
- Proprietary strains & growing techniques
- New 'Roto-gro' garden technology

Extract

- Proprietary extraction methods
- 5 extraction machines
- Quality flowers, oils and concentrates
- High volume production capacity
- Technical expertise

Refine

- Best in class processes
- Strong procedures
- Derivatives capabilities

Market

- Proven consumer model
- Media programme
- New branded products

Sell

- Dispensaries
- Existing loyal customers
- Consumer packaging
- Optimised pricing
- Performance analytics
- Experienced staff

U.S. CULTIVATION AND PRODUCTION

Current and assets under development

	Arizona	Massachusetts	Nevada*	Maryland	Total
Current cultivation capacity (grams per annum)	**1,600,000**		**1,600,000**		**3,200,000**
Current extraction capacity (gpa)	**150,000**		**85,000**		**235,000**
Funded Expansion					
Cultivation (gpa)	**3,600,000**	**2,250,000**			**5,850,000**
Extraction (gpa)	**500,000**	**500,000**		**825,000**	**1,825,000**
Total capacity once completed acq & asset dev					
Cultivation (gpa)	**5,200,000**	**2,250,000**	**1,600,000**		**9,050,000**
Extraction (gpa)	**500,000**	**500,000**	**85,000**		**10,850,000**

Upon completion of current portfolio asset development, >9,000 kgpa flower and >2,000 kgpa high margin concentrate selling through 10 dispensaries and wholesale operations across 4 states

- Upon completion of acquisition
- Source: MPX

WELL-LOCATED ARIZONA DISPENSARIES

2 full-service dispensaries in the Phoenix metro area (Arizona)

- First sales Q1 2014
- Reached profitability in Q2 2015

Developing third dispensary following acquisition of additional license, operational in November 2017

One of the largest cannabis operations in the U.S. Southwest

Large and growing addressable market

- Phoenix metro area
  - 4.6 million people
  - 8.8% population increase since 2010
- Served by only 35 dispensaries



PROFITABLE DISPENSARIES FUELING CASH FLOW

HIGH-MARGIN PRODUCTS – ENGINE FOR PROFIT GROWTH

- A well-diversified portfolio of high-quality cannabis products covering a wide range of medical needs
- Large seed bank with high-demand strains
- High-margin concentrates and other derivatives: oils, shatter, wax and live resin
- 3rd party infused and ancillary products
- JV with Israeli biopharma company Panaxia for smokeless pharma-grade products

STRONG BRANDS – CORE TO SHAREHOLDER VALUE CREATION

- Successful and well-recognized dispensary brand
- Exceptional customer service propagates brand awareness
- Employing advanced retail technologies and concepts
- Driving further awareness through radio, print and social media campaigns

INFUSIONS

- Award-winning products - strong brand recognition
- Premium quality concentrates drives brand recognition
- Products carried by over 40% of Arizona dispensaries
- Considerable investments in science & technology
- Expanding into new states
- Lucky Kitchen Edibles launched in Nevada

Leveraging brand strength in each new state

MARKETS

ARIZONA - RAPIDLY GROWING MARKET, LARGE UPSIDE POTENTIAL

148,000+ registered patients, and growing (22.8% year to date)[1]

Patients are allowed up to 5.1 grams per day

Medical market anticipated to grow to US$681 million by 2020 if adult use is not legalized[2]

Conservatively estimated to grow to $1.2 billion if adult use is legalized[3]



[3]Source: The State of Legal Marijuana Markets, 4th Edition

Attractive competitive landscape with strong barriers to entry

Only 98 dispensary licenses issued and total capped at 126

Colorado (smaller population) has 516[1]

Relatively high and stable pricing for cannabis products

[1] Colorado Department of Revenue

[1]http://www.azdhs.gov/documents/licensing/medical-marijuana/reports/2017/2017-september-monthly-report.pdf

[2]http://www.thecannabist.co/2016/12/06/arizona-marijuana-market-research-projections/68859/

MASSACHUSETTS – THE ADULT USE MARKET OF THE NORTH EAST

Voted to legalize adult use in November 2016

Tightly regulated market with limited number of competitors

Market expected to grow to $1.2 billion[1], driven in part by 'tourism' from neighboring states with over 26 million people

MPX holds 51% of Massachusetts operations and is developing:

- Cultivation and production facility with
  - 2.25 million gram per annum (gpa) cultivation capacity
  - 500,000 gpa high margin concentrates production
- Up to three dispensaries

[1] Arcview/Frontier Data - http://mwne.ws/2nTgg0I

NEVADA – RAPIDLY GROWING ADULT USE MARKET

- Recently closed US$17.8 million purchase of 99% ownership in wholesale cultivation and production company in North Las Vegas
- Recreational use market under Early Start program commenced in July
- Sales forecast to hit US$630 million by 2020[1]
- Las Vegas welcomes over 42M visitors annually
- Launched LK Infusions, a wholesale edibles brand
- Leveraging MPX's award-winning, high-margin concentrates brand MPX
- MPX will be applying for at least one dispensary license in next round (towards end of 2018)





[1]source: https://newfrontierdata.com/wp-content/uploads/2015/11/NV-State-Profile-Release-FINAL-1.pdf)

THE CANADIAN OPPORTUNITY: MEDICAL

Market growth significantly outpaces projections

Number of registered medical patients (June 2017) stands at 201,398[1], already 13% ahead of Health Canada projections for Dec 31, 2017



$ 2.1 billion

medical cannabis market opportunity

- 715,000 registered patients under national medical system by 2020[2]
- Cannabis shipments per patient 1.0 g/d (Health Canada numbers show slightly over 1.0g/d)[3]
- Price: $8/g
- Medical market 2020: $2.1 billion

2 Mackie Research, April 8, 2016

3 Health Canada (http://bit.ly/29aSizY)

1 Health Canada: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html

CANADA – CONSUMER OPPORTUNITY WITH STRONG BARRIERS TO ENTRY

Sales to adult consumer use market in Canada to start in July 2018

First G8/G20 country to legalize

Considerable barriers to entry
- Number of participants restricted
- Capital intensive market entry



$ 10 billion+

adult use market opportunity

- 3.4 million Canadian marijuana users[1]
- Nationwide adult use legalization
- Potential for new product forms & devices
- Sales of home-cultivation kits
- $10 billion legal market projected[2]
- Deloitte estimates[3] that cannabis plus the ancillary market could reach >$22 billion

1 Canadian Community Health Survey–Mental Health 2012

2 CIBC World Markets

3 http://on.thestar.com/2eJBfaH

FINANCIALS – OPERATING ASSETS ACQUIRED JAN 2017

(CDN$)	Q4 Fiscal 2017 (March 31, 2017)	Q1 Fiscal 2018 (June 30, 2017)	Change
Health for Life ("H4L") dispensary cannabis sales (grams)	266,587	267,927	+0.5%
Average price per gram (H4L cannabis sales)	$14.50	$14.76	+1.8%
Total Revenues	$4.4m	$5.1m	+14.1%
Gross Profit	$1.0m	$2.7m	+166%
Gross Profit Margin	22.7%	52.9%	+133%
Adjusted EBITDA	($0.3m)	$0.1m	+$0.4M

Arizona cannabis prices strong, holding and well ahead of Canadian prices
Strong underlying profitability

SCALE

One of North America's largest publicly-traded cannabis companies by revenue

GROWTH STRATEGY

ORGANIC GROWTH STRATEGY

Organic Growth Strategy
- Doubling current grow & cultivation facilities to 3.2 million grams per annum in Arizona alone
- Add additional dispensaries
- Leverage proprietary, award-winning high-margin derivative wholesale brand (MPX)
- Partnership with MJardin to increase cultivation yield

Innovation
- Exclusive access to innovative cultivation technologies to substantially increase yield per square foot and lower costs
- Leverage partnership with Mjardin to increase facility yields

Differentiation
- JV with Panaxia
    - High-demand, pharma-grade products
    - Smokeless delivery (patches, suppositories, topicals, etc)
    - Wide ranging exclusivity

MPX MELTING POINT EXTRACTS

MJARDIN PREMIUM CANNABIS

PANAXIA Pharmaceutical Industries

INNOVATION – EXCLUSIVE RIGHTS TO NEW CULTIVATION TECHNOLOGY

- Four times the yield of flower production per square foot
- Significantly less energy input and nutrient usage
- Stackable units with much lower space requirement than conventional growing systems
- Each unit capable of producing up to 8 pounds of flower in each 8 – 10 week grow cycle
- Estimated cost of less than US$1.00 per gram
- Stacked two high, the annual flower yield on a 60 square foot footprint would be >32,000 grams of cannabis

MPX has exclusive rights to utilize the technology in Arizona and Nevada for up to two years

Currently trialing the technology in Arizona prior to deployment across the organization

ACQUISITION STRATEGY

- Focus on the rapidly growing and fragmented US cannabis market
- Identify under-capitalized companies in attractive cannabis states
- Enter states with restrictive competitive environment
- Companies that are at or near cash flow positive
- Greenfield licenses with high growth potential
- Structure acquisitions with low upfront cash outlays
- Management team to transfer knowledge and operational experience to acquired companies to develop best-in-class production, branding and sales/marketing
- In order to complete acquisitions, and continue to build out existing operations, will need to raise further capital

Earnings accretive acquisitions

Licensed operators with strong operational track record

No turnarounds

Greenfield development in high-potential, early-stage markets with strong barriers to entry

WELL-CAPITALIZED TO FUEL EXPANSION

Date	January 23, 2017	March 30, 2017 and May 5, 2017	May 3, 2017
Offering Details	• Private placement for gross proceeds of US$27 million (CA$36.3 million), consisting of 181,683,101 common shares at a price of CA$0.20 per Common Share. • MPX had 223,632,654 common shares outstanding.	• Private placement for gross proceeds of US$11,173,700 (CAD$14,925,766) by issuing 29,851,533 common shares of the Company at a price of CAD$0.50 per common share.	• US$25 million revolving credit facility with Hi-Med, LLC of Florida at a 7.0% interest and maturity in 36 months. • Hi-Med has the ability to convert the outstanding principal into common shares of the company (@$0.50, $1.00 & $1.50)[1].
Use of Proceeds	• Proceeds of this private placement were used to satisfy the US$15 million cash portion of the purchase price for the Arizona Business. • Remaining US$12 million (~CA$15.8M) of the gross proceeds to build out a new cultivation facility in Mesa, Arizona to support further acquisitions, and for general working capital.	• Proceeds of the offering to fund the acquisition and development of further marijuana enterprises or service companies to marijuana enterprises with targets located in Arizona, Maryland, Massachusetts, Nevada and Pennsylvania as well as general working capital purposes.	• Funds drawn down against the line of credit will be earmarked specifically for making further acquisitions, as well as, where needed, the development of assets obtained in any transaction. • To date $10M drawn down

[1] @$0.50 for first $10M; @$1.00 for >$10M, up to $20M; @$1.50 for > $20M

MPX may seek to raise up to US$20m to fund the near term acquisition pipeline

2017 ACQUISITION PIPELINE SUMMARY

Company	Cash	Deferred Cash	Shares	Debt	Options/Warrants	Total	MPX Ownership	Close
	(US$, M)	(US$, M)		(US$, M)		(US$, M)		
Health for Life, AZ Completed	$15		-	$10	-	$25	100%	COMPLETED January 15, 2017
IMT, LLC (CannaTech) Completed	$5.1	$1.6	-	-	-	$7.1	51%	COMPLETED June 15, 2017
GreenMart of Nevada Completed	-	-	$8.5 M in units @ $0.75/unit	$9.32 @ 0%; June 30, 2018	0.25 warrant per unit @$0.75/share	$17.82	99%	COMPLETED October, 2017
PerkAZ Completed	$3.0		$1.0 M in shares @ $0.75/share			$4.0	100%	COMPLETED March, 2017
Target #1 - Arizona Non-binding LOI signed	$15.0	-	-	$6.0 @ 8%; 36 months	3,000,000; 36 months	$21.0	100%	December, 2017
Targets #2 A, B & C - Maryland Non-binding LOI signed	$9.0	-	US$1.4 million in shares at closing	-	-	$10.4	100%	December, 2017

Well-positioned to pursue expansion into other U.S. states

2018 targets: Ohio, New Jersey, Michigan

ACQUISITION #1 - ARIZONA

Highlights

- Acquisition of a profitable and cash flow positive management services company in Phoenix, Arizona
- Long-term agreement to provide all managerial and operational services to a not-for-profit dispensary location
- Dispensary located in up-market area with high population density

- Opportunities for organic growth:
  - Transferring H4L's retail best-practices
  - Carry high-margin MPX products
  - Implement cultivation optimization practices
- Implementation of H4L best practices expected to contribute to margin expansion

4th dispensary location Phoenix



~3x

2017 Revenue

Cash flow positive

Strong growth potential

ACQUISITIONS #2 A, B & C - MARYLAND

Highlights

- Acquisition of management entities servicing three dispensary licenses
- One production license:
  - Only 15 production licenses granted in entire state
- One flower and trim supply contract
- First-mover advantage with a limited number of licenses allowed
- All within the populous Baltimore-Bethesda market

~1.0x

Expected 2018 combined revenue

Cannabis in Maryland

- A for-profit jurisdiction
- A total of only 109 dispensaries are allowed in the entire state
- Only two dispensaries per Senate district
- Population of over 6 million people
- Maryland is expected to hit US$125-175 million in revenue by 2020 (ArcView)

172

Doctors have registered to participate in Maryland Medical Marijuana program



Dispensary licenses located in high-income areas, which are proven, in other states, to be strong markets for high-margin product

THE U.S. CANNABIS INDUSTRY - LEGAL & COMPLIANCE

- Cannabis remains a Schedule I restricted substance at the federal level
- Legalization implemented on a state by state basis
- CSA requires the following
- All issuers with U.S. cannabis exposure:
  - Must explain that cannabis remains illegal under U.S. federal law and that the approach to enforcement of U.S. federal laws is subject to change. The resultant risks, including the risk of adverse enforcement action, must be discussed;
  - Must state whether and how their activities are conducted in a manner consistent with any U.S. federal enforcement priorities;
  - Must discuss their ability to access both public and private capital, and indicate whether financing options are available or are not available in order to support continuing operations, given the illegality of cannabis under U.S. federal law.
- Issuers with direct involvement in U.S. cannabis cultivation or distribution:
  - Must outline the regulations in the U.S. states in which they operate, and confirm how they are complying with applicable licensing requirements and the regulatory framework enacted by the applicable state;
  - Must discuss their program for monitoring compliance with U.S. state law on an ongoing basis and outline internal compliance procedures. They also must disclose any material non-compliance as well as material citations or notices of violation.

MPX fully compliant with all requirements

ADRESSING THE ELEPHANT IN THE ROOM

What about Trump & Sessions?

US$7.1[1] billion industry (2016)

150,000 jobs created, **300,000** anticipated by 2020[2]

$2.3 billion in state tax revenue anticipated from retail sales by 2020[2]

Rohrabacher-Farr amendment, law since 2014, explicitly prohibits the Justice Department from spending funds to interfere with the implementation of state medical marijuana laws.

13 bills before congress aiming to protect the industry. McClintock-Polis Amendment looks to bar U.S. DoJ from prosecuting any state-licensed cannabis enterprise.

Sessions supports **10th Amendment**, protecting States' rights.

"…In terms of marijuana and legalisation, I think it should be a state issue, state-by-state" (Donald Trump during election campaign[3])

"If Jeff Sessions attempts that, I hope he'll have to contend with many of us–certainly myself–but I think enough Republicans and Democrats will say, 'Look, you need to stick to federal responsibilities[4]. This is a states' role.'"
(Rep. congressman Jared Polis)

1 executive summary: the state of legal marijuana markets, 4th edition (archives market research and new frontier), 2016
2 http://247wallst.com/consumer-products/2017/03/07/state-tax-collections-could-add-2-3-billion-from-legal-marijuana-sales-in-2020
3 http://www.businessinsider.com/trump-and-clinton-on-weed-legalization-2016-11
4 http://www.thecannabist.co/2017/04/21/jeff-sessions-marijuana-legalization-impact/77938/

RECENT DEVELOPMENTS AND THE NEAR FUTURE

1. Name & Symbol changed from BCC to MPX Bioceutical Corporation - CSE:MPX
2. Refreshed Board of Directors
3. Upgrade to OTC:QX to reach wider investor audience and improve liquidity
4. Nevada dispensaries & expansion of flower cultivation & concentrates production capacity
5. New Licenses in 2018 – Targets Ohio, New Jersey, Michigan
6. Progressing with Canadian license

MPX poised to capitalise on the opportunity

- MPX has the opportunity to lead industry consolidation:
  - Acquire an established, profitable market leading platform
  - Create a national brand and multi-state presence
  - Selectively pick the best market opportunities at attractive prices

- MPX will be ideally positioned when institutional and corporate capital arrives
  - Institutional money will look for scale and profitability
  - Big agriculture – looking for yield enhancement crops
  - Big tobacco – looking to counter declining cigarette sales
  - Big alcohol – expansion into new consumer products

- Corporate capital has deep pockets and will pay 'scarcity' premiums for:
  - The bigger more developed opportunities
  - Proven management familiar with the regulatory environment



Cannabis in the cross hairs of large, complementary industries

BOARD AND MANAGEMENT

Scott Boyes – President & CEO

- Recognised expert in the sector with deep operational and legislation experience and strong track record in revenue and profit development

Randall (Randy) Stafford – CFO

- 3 decades of senior financial experience with companies such as Cushman & Wakefield, First Canadian Title, SmartCentres and Newcourt Credit
- CPA and MBA from the Rotman School of Management

Beth Stavola – President CGX (U.S. Operations)

- Founder and CEO of Stavola Medical Marijuana Holdings, Health for Life Inc, GreenMart of Nevada, and CBD For Life

Michael Arnkvarn – VP Marketing & Product Development

- 30 years in the nutraceutical industry and an expert on plant-based medicines and extraction technology

Mark Krytiuk – VP Growth Operations

- 12 years of commercial marijuana cultivation experience in Canada

Richard S. "Tick" Segerblom – Director

- State Senator and prominent lawyer, widely recognized as the nation's leading legislator in the medical and recreational marijuana fields

Robert R. Galvin – Director

- CFO and SVP of Finance & Administration for Holtec International with experience in mergers & acquisitions, debt and equity financings and SEC compliance

Andrew R. Ryan – Director

- General Counsel of Holtec International and member of the Holtec Executive Committee where he is responsible for all legal matters affecting the company and its subsidiaries

Miles D. Thompson, B.Sc, Ph.D. – Director

- Extensive experience in the design and implementation of clinical trials administered by Health Canada and initiated the study of cannabinoids in epilepsy at the Department of Pharmacology and Toxicology at the University of Toronto

COMPANY DATA

	October, 2017
Listings	
CSE OTCQB	MPX CBICF
Securities:	
Issued & Outstanding Shares	259,521,473
Warrants & Comp Options	30,089,527
Management & Employee Options	21,430,000
Fully Diluted	311,671,160
Convertible Debentures	630,160 (max)

APPENDIX

WHO WE ARE

A vertically integrated, multi-state cannabis operation

MPX provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona (3rd under development), and one in Massachusetts, as well as is acquiring outright a cultivation, production and wholesale cannabis business in Las Vegas, Nevada

Under the management agreements, MPX has material influence over the Arizona and Massachusetts operations, and will be required to consolidate their results under IFRS

The management agreements have a 20 year initial term with prohibitive break-out clauses



JURISDICTIONAL COMPARISON OF FOCUS MARKETS



	Arizona	Nevada	Massachusetts	Maryland	Canada
Medicinal Marijuana	✓	✓	✓	✓	✓
Recreational Marijuana	✕	✕ Commenced July '17	✕ Begins Jan '18	✕	✕ Expected July '18
Current Number of Patients	114,439	25,465	34,189	N/A	129,876
Projected Sales	US$681 million (2020)	US$630 million (2020)	US$1.1 billion (2020)	US$125-175 million (2020)	CA$4.9-8.7 billion (Upon Legalization)
Population	7,026,629	2,995,973	6,873,018	6,068,511	35,850,000
Regulatory Framework	Not-for-profit	For-profit	Not-for-profit	For-profit	For-profit

https://www.mpp.org/issues/medical-marijuana/state-by-state-medical-marijuana-laws/medical-marijuana-patient-numbers/
http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/market-marche-eng.php
http://www.thecannabist.co/2017/04/04/nevada-recreational-marijuana-distribution-sales/76615/
https://ballotpedia.org/Nevada_Marijuana_Legalization,_Question_2_(2016)

https://mic.com/articles/161616/arizona-weed-laws-2017-what-to-know-about-legalization-after-prop-205-defeat#.RWE71maU2
https://newfrontierdata.com/wp-content/uploads/2015/11/Arizona-Report-FINAL-Release.pdf
https://mjbizdaily.com/new-market-once-maryland-fixes-problems-ample-mmj-opportunities-await/
https://ballotpedia.org/Massachusetts_Marijuana_Legalization,_Question_4_(2016)
https://www.thestar.com/news/queenspark/2016/10/27/recreational-weed-could-be-a-226b-industry-study.html

COMPARISON CANADA – MPX ARIZONA

MPX Arizona

- Strictly regulated
- ~ 148,000 registered patients in Arizona[1]
- Fragmented
- Mostly mom-and-pop operations
- High product prices (US$10-15/gram)
- Lower facility costs
- Lower labour costs
- Max 5.1 grams per day in Arizona
- Adult use legalized on a state by state basis
- Market cap of MPX - CAD$112 million (Oct 26, 2017)

CANADA

- Strictly regulated
- ~200,000 registered patients (Health Canada, September 2017)
- >700,000 patients projected by 2020 (Mackie Research, April 2016)
- Concentrated
- Enterprise level operations
- Product pricing (CA$5-10/gram)
- High facility CapEx
- Relatively high labour costs
- Quantities prescribed by doctors, generally 1-3 grams per day
- Nationwide legalization of adult use in 2018
- Market cap of companies servicing CAD$5.9 billion (October 2017)

[1] Medical Marijuana Report, September 2017, http://www.azdhs.gov/documents/licensing/medical-marijuana/reports/2017/2017-sept-monthly-report.pdf

MARIJUANA VS OTHER COMMODITY MARKETS



Globally, the marijuana industry is almost equal to the size of the gold industry

FORWARD LOOKING STATEMENTS

Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, "**forward-looking statements**") within the meaning of applicable Canadian and United States securities laws. Such forward-looking statements relate to future events or the future performance of The Canadian Bioceutical Corporation ("**MPX**"). All statements other than statements of historical fact contained in this presentation may be forward-looking statements. The forward-looking statements contained in this document are based on certain key expectations and assumptions made by management of MPX. Although management of MPX believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because MPX can give no assurance that they will prove to be correct.

Certain statements in this presentation including, but not limited to, (i) statements that may contain words such as "expected", "will", "future", "developing", "grow", and similar expressions, including the negatives thereof or other comparable terminology; (ii) statements that are based on current expectations and estimates about the markets in which MPX operates; and (iii) statements of belief, intentions, and expectations about developments, results, and events that will or may occur in the future, constitute forward-looking statements which are based on certain assumptions and analysis made by management of MPX. Some of the assumptions which management of MPX has made and which underlie the forward-looking statements include MPX's future operational and production capacity, the impact of enhanced infrastructure and production capabilities, the impact of governmental laws and regulations and future growth. Forward-looking statements include, but are not limited to, statements with respect to development trends within the medical and adult use marijuana sectors, governmental laws and regulations, business strategy; expansion and growth of MPX's business and operations; and other such matters. Such forward-looking statements are subject to material risk factors and uncertainties, many of which are beyond the control of MPX, including, but not limited to, the MPX's future operational and production capacity, the impact of enhanced infrastructure and production capabilities, the impact of governmental laws and regulations and future growth. The realization of risks is difficult to predict and may affect MPX operations causing actual results to differ materially from forward-looking statements. Such material risk factors include, but are not limited to: the impact of general economic conditions; industry conditions; arising claims; partner events; operational opportunities; changing technology; government and regulatory developments; competition; and the ability of MPX to attract and retain qualified personnel.

MPX's actual results, performance, or achievements could vary from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do transpire or occur, what benefits MPX will derive therefrom. All forward-looking statements contained in this presentation represent the views of MPX only as of the date of this presentation and should not be relied upon as representing the views of MPX's management as of any date subsequent to the date of this presentation. Subject to applicable law, MPX disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

All forward-looking statements contained in this document are expressly qualified by this cautionary statement.